Test of CLAG treatment plan after first leukemia treatment failure
Part of Blood & lymphatic, Cancer clinical trials.
This study follows people with acute myeloid leukemia (AML) whose first treatment attempt didn’t work. It looks at how the CLAG treatment plan performs, especially for patients who may need a next step after initial failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML).
- Your first chemotherapy treatment did not work (first-induction failure).
- You do not currently have a serious infection.
- You do not have organ problems caused by illness (organ dysfunction).
- Your care team can confirm these details for study screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step treatment: first a targeted immune cell therapy (CLL1 CAR-T) to attack leukemia cells, followed by a stem cell transplant to rebuild healthy blood cells. It is for people with acute myeloid leukemia that has returned or not responded to previous chemotherapy.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests whether adding venetoclax to a standard chemotherapy regimen (CLAG) works better than the chemotherapy alone for adults whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment.
This trial studies a drug called CLAG-GO (an antibody with chemotherapy drugs attached) in adults with AML that has come back or did not respond to treatment. It aims to improve outcomes for people whose leukemia is persistent, relapsed, or refractory.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.